Inhaled Loxapine as a Rapid Treatment for Agitation in Patients with Personality Disorder

Agitation in patients diagnosed with personality disorders (PD) is one of the most frequent crises in emergency departments (ED). Although many medications have been tested, their effectiveness has been small or non-significant, and no specific drugs are supported by the available evidence. This stu...

Descripción completa

Detalles Bibliográficos
Autores: Ferrer Vinardel, Marc|||0000-0002-1283-8578, Soto-Angona, Óscar|||0000-0003-0234-4280, Soler Artigas, María|||0000-0002-3213-1107, Ibáñez, Pol|||0000-0003-0714-8908, Fadeuilhe, Christian|||0000-0001-5821-347X, Palma-Álvarez, Raúl Felipe|||0000-0002-6428-9865, Lidai, Raquefet|||0000-0003-4476-1226, Vargas-Cáceres, Sebastian|||0000-0001-6113-0392, Torrecilla, María Ángeles|||0000-0001-5811-2695, López Illamola, Anna|||0000-0003-3932-9674, Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:282688
Acceso en línea:https://ddd.uab.cat/record/282688
https://dx.doi.org/urn:doi:10.9758/cpn.2022.20.3.482
Access Level:acceso abierto
Palabra clave:Antipsychotic agents
Loxapine
Personality disorders
Psychomotor agitation
Descripción
Sumario:Agitation in patients diagnosed with personality disorders (PD) is one of the most frequent crises in emergency departments (ED). Although many medications have been tested, their effectiveness has been small or non-significant, and no specific drugs are supported by the available evidence. This study aimed to evaluate the efficacy of Inhaled loxapine (IL) as a therapeutic option for agitated patients with PD. A naturalistic, unicentric, prospective study was carried out. Thirty subjects diagnosed with PD and attending the ED with episodes of agitation were recruited most of whom were women diagnosed with Borderline Personality Disorder. Subjects were treated with a single dose of IL (9.1 mg). Efficacy was assessed with the Clinical Global Impression scale, the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) and the Agitation-Calmness Evaluation Scale (ACES). Patients were followed 60 minutes after administration to measure IL effect and its duration. IL exhibited an overall efficacy in managing mild to severe agitation, with a quick onset of effect and persistence. 'Effect of time', where IL efficacy is maintained over time, is more marked in higher-severity agitation. No additional treatments were needed to improve agitation during the follow-up time. Results suggest that IL could be a safe and effective option to manage agitation in PD.